Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Mabpharm Out-Licenses US-EU Rights for COVID-19 Fusion Protein to Sorrento

publication date: Mar 25, 2020

Mabpharm of Taizhou out-licensed US and EU rights for an ACE-MAB fusion protein that targets COVID-19 to San Diego's Sorrento Therapeutics. The two companies will jointly conduct clinical trials of the candidate. The bi-specific is expected to interrupt the life cycle of SARS-CoV by blocking the virus from binding respiratory epithelial cells and ACE2-expressing cells. Sorrento will develop the candidate for the US and EU, while Mabpharm will own rights in China, Japan and the rest of the world. More details...

Stock Symbols: (HK: 2181) (NSDQ: SRNE)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China